https://socictopen.socict.org/files/original/56e3263ebddb2689ef151e69766a7348.pdf c4fb5e8f82568707ab31ab936826c681 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review Creator An entity primarily responsible for making the resource Eljilany I, Elzouki AN Description An account of the resource Islam Eljilany,1 Abdel-Naser Elzouki2,3 1Qatar University, College of Pharmacy, Doha, Qatar; 2Hamad Medical Corporation, Hamad General Hospital, Department of Medicine, Doha, Qatar; 3Department of Medicine, Qatar University, College of Medicine, Doha, QatarCorrespondence: Abdel-Naser ElzoukiDepartment of Medicine, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, QatarTel +974 66022836Email AElzouki@hamad.qaAbstract: Coronavirus disease 2019 (COVID-19) emerged from the West District of Southern China Seafood Wholesale Market in late December 2019 and has been declared a global pandemic by the World Health Organization (WHO). Infection with severe acute respiratory syndrome coronavirus (SARS-CoV-2) presents with upper respiratory symptoms like cough, fever, and lethargy. At the same time, in later stages, critical COVID-19 patients develop acute respiratory distress syndrome (ARDS), venous thromboembolism (VTE), and multiple organ failure from cytokine storm and coagulation hyperactivity. Primary manifestations of thrombotic events include deep vein thrombosis (DVT), disseminated intravascular coagulation (DIC) and pulmonary embolism (PE). Initial coagulopathy in COVID-19 patients presents with elevated fibrin degradation products, especially D-dimers. In contrast, late presentations show evidence of prolonged prothrombin time (PT) and activated partial thromboplastin (aPTT), increased platelets, and fibrinogen levels. Diagnosis and monitoring of disease progression are done by regular screening of laboratory parameters, including D-dimer and fibrinogen. Management of coagulopathy in COVID-19 patients is like that of critically ill patients, including thromboprophylaxis. Coagulopathy is a poor prognostic factor, and optimum strategies should be developed for early diagnosis, prevention, and prompt treatment of VTE in COVID-19 patients. Thrombosis prophylaxis with low molecular weight heparin (LMWH) has shown beneficial results in preventing coagulopathy a reducing risk of mortality due to thrombotic events. We will discuss VTE in COVID-19 patients highlighting the role of D-dimer, fibrinogen, and interleukin-6 (IL-6).Keywords: COVID-19, SARS-CoV-2, D-dimer, fibrinogen, IL-6, venous thromboembolism Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource covid-19, SARS-CoV-2, D-dimer, venous thromboembolism, IL-6, fibrinogen Source A related resource from which the described resource is derived Biotemas Publisher An entity responsible for making the resource available Universidade Federal de Santa Catarina Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Diseases of the circulatory (Cardiovascular) system